Journal article
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
CQ Pan, TT Chang, SH Bae, M Brunetto, WK Seto, CS Coffin, SK Tan, S Mo, JF Flaherty, A Gaggar, MH Nguyen, MK Celen, A Thompson, EJ Gane
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2021
Abstract
Background/Purpose Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing motherto- child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV. Methods In a patient subset meeting WOCBP criteria and with baseline HBV DNA >200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA <200,000 IU/ mL at weeks 12 and 24 were assessed. Multivari..
View full abstractGrants
Funding Acknowledgements
Funding for this study was provided by Gilead Sciences, Inc. No specific grant associated with this study, but CQP, T-TC, SHB, MB, W-KS, CSC, MHN, MKC, AT, and EJG served as investigators of the clinical trial from which this secondary analysis is derived. The funder, Gilead Sciences, participated in study design, data collection and analysis, decision to publish, and preparation of the manuscript.